Latest in: gene therapy
Featured Image

Companion diagnostics (CDx) snapshot in 2026

Four years ago, we have produced what seemed to be one of our most resonant pieces of content, on the status of companion diagnostics industry in 2022. Over the past 4 years, the industry …
gravatar
 · 
March 19, 2026
Featured Image

What happened with Sarepta and what does it mean for gene therapies?

Recently, the FDA has requested Sarepta Therapeutics, Inc., a Massachusetts-based biopharmaceutical company, to suspend all distribution of its DMD gene therapy Elevidys (delandistrogene moxeparvovec), following the deaths of three patients—two non‑ambulatory teenagers and one …
gravatar
 · 
August 11, 2025
Featured Image

FDA has approved 55 new molecules in 2023

With a focus on addressing a wide spectrum of diseases and conditions, the US witnessed the most novel drug approvals in 6 years. Here we provide an overview of the key highlights in treatments …
gravatar
 · 
January 15, 2024
Featured Image

The 4 most expensive single-dose drugs in 2022

In 2019, Novartis’s gene therapy Zolgensma made news as the „most expensive single-dose drug ever“ with $2.125 million. Just 3 years later, as of November 2022, bluebird bio’s Skysona, with the price tag of …
gravatar
 · 
November 13, 2022

Impressum

ambiom s.r.o.
Karpatské námestie 7770/10A
831 06 Bratislava
IČO: 54219035

Contact

info@ambiom.com
+421 948 652 276

footer-FB
footer-Li
Footer-Insta

Newsletter

Back to top Arrow